Merus Biopharmaceuticals BV We discover and develop innovative therapeutic human antibodies with improved clinical efficacy based on its single light chain (sLC) antibody technologies. Single light chain (sLC) antibodies share a common immunoglobulin light chain while retaining the exquisite specificity and high affinity of antibodies with diversified light chains. Multiple sLC human antibodies against different epitopes/targets are efficiently co-expressed in a single manufacturing cell to generate novel antibody formats like full length IgG bispecific antibodies (COBRA™) and mixtures of IgG antibodies (HYDRA™). By combining multiple mechanisms of action, these formats provide the basis for enhanced disease-modifying targeted therapies. Based on these technologies we are building a pipeline of innovative therapeutic antibodies with improved clinical efficacy in multiple therapeutic areas.